Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
Sign Up to like & getrecommendations! Published in 2022 at "Cornea"
DOI: 10.1097/ico.0000000000003162
Abstract: Supplemental Digital Content is Available in the Text. Abstract: Emerging monoclonal antibody therapies are assuming greater importance in the management of severe and refractory forms of immunity-driven and oncological disorders. However, some have been found… read more here.
Keywords: adverse ocular; belantamab mafodotin; etiology; management ... See more keywords
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18298
Abstract: Belantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF‐induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively… read more here.
Keywords: advanced multiple; belantamab mafodotin; blmf; toxicity ... See more keywords
Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergizein vitroand potentiatein vivoanti-tumor activity in multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-6711
Abstract: Multiple myeloma (MM) is a hematological malignancy that affects plasma cells and leads to devastating clinical features. Typically, front-line and relapsed/refractory multiple myeloma (RRMM) treatments comprise standard of care (SOC) combinations that include proteasome inhibitors… read more here.
Keywords: lenalidomide pomalidomide; multiple myeloma; belantamab mafodotin; cell ... See more keywords
Belantamab mafodotin for relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221086265
Abstract: Objective: Refractory multiple myeloma (MM) presents poor responses to therapies. New drugs for highly pretreated MM are a hope for this clinical context with limited treatment options. We developed a comparative commentary on the evidence… read more here.
Keywords: mafodotin; relapsed refractory; belantamab mafodotin; refractory multiple ... See more keywords
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720979813
Abstract: Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody–drug conjugate (ADC) that recently gained regulatory approval for the treatment of relapsed and/or refractory multiple myeloma (RRMM) patients who have received at least four… read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; multiple myeloma ... See more keywords
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8502
Abstract: 8502Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated RRMM refr... read more here.
Keywords: tolerability belantamab; safety tolerability; belantamab mafodotin; dreamm safety ... See more keywords
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1026251
Abstract: Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated… read more here.
Keywords: efficacy safety; belantamab mafodotin; refractory; real life ... See more keywords
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15112948
Abstract: Despite the recent approval of novel immunotherapies, such as immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multiple Myeloma (MM) remains incurable, and the acquisition of triple-refractoriness leads to really dismal outcomes in even earlier… read more here.
Keywords: real life; clinical trials; mafodotin clinical; belantamab mafodotin ... See more keywords
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma. Results of the Compassionate Use or the Expanded Access Program in Spain
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15112964
Abstract: Simple Summary Patients with multiple myeloma (MM) who become refractory to three or more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them, drugs directed against the BCMA antigen expressed in plasma… read more here.
Keywords: relapsed refractory; belantamab mafodotin; myeloma; refractory multiple ... See more keywords
The Effect of Belantamab Mafodotin on Primary Myeloma–Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24065303
Abstract: Belantamab mafodotin (belamaf) is an afucosylated monoclonal antibody conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF) that targets B cell maturation antigen (BCMA) on the surface of malignant plasma cells. Belamaf can eliminate myeloma cells… read more here.
Keywords: bone marrow; belantamab mafodotin; myeloma; myeloma cells ... See more keywords
A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
Sign Up to like & getrecommendations! Published in 2022 at "Arquivos brasileiros de oftalmologia"
DOI: 10.5935/0004-2749.2021-0358
Abstract: A 60-year-old-male with refractory relapsed multiple myeloma presented with redness, pain, foreign body sensation, and blurred vision in both eyes that gradually increased after his third belantamab mafotodin infusion. Biomicroscopy revealed bilateral microcyst-like epithelial changes… read more here.
Keywords: belantamab; novel agent; agent myeloma; belantamab mafodotin ... See more keywords